Losartan Potassium Tablet, Film Coated
Product Images NDC 71335-1136

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71335-1136). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713351136)

Losartan Potassium 25 mg oral film-coated tablet label by Bryant Ranch Prepack. The label compares this product to Cozaar 25 mg tablet by RA Chem Pharma Limited. It includes storage instructions to keep at 20°-25°C (68°-77°F), a lot number 1523487, a count of 90 tablets, and an NDC of 71335-1136-1. The label also displays a barcode and identifies the tablet as a white oval shape.*

FDA Label Image

Losartanpotassium Figa

A line graph comparing the percentage of patients with a primary endpoint over study months between atenolol and losartan potassium treatments. The x-axis represents study months (0 to 66), and the y-axis shows the percentage of patients. The graph shows an adjusted risk reduction of 13% with losartan potassium compared to atenolol, with a p-value of 0.021.*

FDA Label Image

Losartanpotassium Figb

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 months of study between Atenolol (dotted line) and Losartan Potassium (solid line). The graph indicates a lower percentage of stroke in the Losartan Potassium group with an adjusted risk reduction of 25%, p=0.001.*

FDA Label Image

Losartanpotassium Figc

A forest plot chart comparing the hazard ratios for Losartan Potassium versus Atenolol in primary composite and stroke outcomes. The chart includes subgroups by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease, showing event rates and confidence intervals for each subgroup.*

FDA Label Image

Losartanpotassium Figd

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The x-axis represents time in months, and the y-axis percent patients with event. The graph shows a risk reduction of 16.1% with a p-value of 0.022 for the Losartan Potassium group relative to placebo.*

FDA Label Image

Losartanpotassium Stru

Chemical structure image of the active ingredient losartan potassium, showing its molecular composition including chlorine, hydroxymethyl, and potassium ion components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.